BridgeBio director Scott resigns at annual meeting; stockholders approve 2M share increase in stock plan

BridgeBio Pharma, Inc.

Dr. Randal W. Scott resigned as Class I director effective June 22, 2026, upon term completion, citing no disagreement.
Stockholders approved amending 2021 Stock Option Plan to increase reserved shares by 2,000,000.
Elected Class I directors: Momtazee, McCormick, Valantine; all received >129M votes for.
Non-binding advisory vote on executive compensation approved (152.9M for); 1-year frequency endorsed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.